S&P 500 ^GSPC
5,117.62
-1.57%
Nvidia NVDA
$884.00
-2.45%
Meta META
$511.62
-2.21%
Tesla TSLA
$171.24
-1.92%
Amazon AMZN
$185.54
-1.86%
Microsoft MSFT
$420.76
-1.68%
Alphabet GOOG
$158.77
-1.26%
Apple AAPL
$175.52
+0.27%

Pfizer $PFE-1.5% announced the acquisition of biotech firm Seagen. This acquisition is another step in Pfizer's efforts to confirm its position as a long-term leader in oncology.

PFE

Pfizer

PFE
$25.96 -$0.38 -1.46%
Capital Structure
Market Cap
148.7B
Enterpr. Val.
221.0B
Valuation
P/E
71.2
P/S
2.5
Dividends
Yield
6.3%
Payout
433.7%

Seagen will bring to Pfizer's portfolio an excellent ADC technology that can deliver a cancer-killing drug directly to cancer cells while sparing other healthy tissues to the maximum extent possible. In the future, we will be able to bring cancer drugs from the antibody conjugate class to patients, which will be a breakthrough technology for the treatment of many types of cancer.


So we'll see how it turns out, as Marek writes, not every acquisition has to be so profitable. However, I have PFE shares in my portfolio and I am waiting for the growth.

I understand, and I wonder if you will support the rust

I see that the stock is down 6% yesterday and today, but I don't want to overbuy.

I can't really form an opinion on the acquisition. Although it fits their portfolio, I don't know if it was a good deal at that price. I fear that like many of their acquisitions, it will be a long run. But I guess why not.

It seems like a lot to me too,but I guess they're betting that they want to have as many colonoscopies as possible so they can set their prices 🤔

It's possible, I haven't completely mastered the segment, but the revenues would put Pfizer on the front foot.